- President Biden is contemplating suspending intellectual property rights for COVID-19 vaccines.
- The sooner we vaccinate the entire world, the closer we get to protecting ourselves against COVID-19 and, potentially, new strains.
- I value MRNA and NVAX based on 1x expected 2022 revenue, plus cash.
- I estimate MRNA and NVAX are overvalued by 65% and 50%, respectively. Once the market digests this, this stocks could fall hard.
- Generic competition could make matters worse. Sell MRNA and NVAX.
For further details see:
Suspending Vaccine IP Rights Could Sink Moderna, Novavax